Evaluation of biomarkers associated with clinical efficacy of CIMAvax-EGF® vaccine in patients with advanced stages (IIIB and IV) of non-small cell lung cancer who have been treated with this therapy. Physician Led - CIMAvax-EGF vaccine lung Biomarkers

Center of Molecular Immunology (CIM)0 个研究点目标入组 140 人开始时间: 2021年3月11日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Other

•1. Patients of any sex and age greater than or equal to 18 years.
•2. Patients who have signed the informed consent for the research.
•3. Patients who meet the diagnostic criteria.
•4. Patients with at least stable disease after 1st line chemotherapy, who have been included in clinical trials with the CIMAvax-EGF vaccine or have been treated as part of routine medical practice.
•5. Patients who have completed the induction stage with the CIMAvax-EGF® vaccine and are receiving the vaccine as maintenance therapy.
•6. Patients with clinical status criteria (ECOG) from 0 to 2

•1. Patients of childbearing potential who are not using adequate contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of males (vasectomy, use of condoms) while the treatment lasts
•2. Pregnant, lactating or postpartum patients.
•3. Patients with uncontrolled intercurrent illnesses including, but not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric illnesses that imply the incompetence of the subject.
•4. Patients with brain metastases.
•5. Patients with acute allergic states or history of severe allergic reactions.

发起方

Center of Molecular Immunology (CIM)